Page last updated: 2024-12-11

misoprostol acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

misoprostol acid: de-esterified metabolite of misoprostol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436406
CHEMBL ID1201377
SCHEMBL ID3694237
MeSH IDM0136024

Synonyms (43)

Synonym
gtpl1935
misoprostol (free acid form)
IDI1_033888
misoprostol acid
misoprostol free acid, >=90%
NCGC00161305-01
NCGC00161305-02
BSPBIO_001418
NCGC00161305-03
HMS1989G20
sc-30695 ,
CHEMBL1201377
misoprostolic acid
BML2-B06
misoprostol, free acid
HMS1791G20
HMS1361G20
7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoic acid
66792-31-2
sc 30695
unii-12z0su967a
prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, (11alpha,13e)-(+-)-
15-deoxy-16-hydroxy-16-methylprostaglandin e1
12z0su967a ,
(11alpha,13e)-(+)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid
misoprostol free acid
misoprostol acid (10 mg in 1 ml methyl acetate)
SCHEMBL3694237
HMS3402G20
HMS3648F05
(11.alpha.,13e)-(+/-)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid
misoprostanoic acid
misoprostol free-acid
HY-118189
7-((1r,2r,3r)-3-hydroxy-2-((e)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
Q27086526
sr-01000946416
SR-01000946416-1
CS-0065404
rel-7-((1r,2r,3r)-3-hydroxy-2-((e)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
prost-13-en-1-oicacid,11,16-dihydroxy-16-methyl-9-oxo-,(11a,13e)-
DTXSID601347869
AKOS040733741

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"It has been shown that the route of administration of misoprostol has a strong impact on the pharmacokinetic profile and result in different clinical efficacy."( Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol.
Aronsson, A; Fiala, C; Gemzell-Danielsson, K; Granath, F; Schweer, H; Stephansson, O; Watzer, B, 2007
)
0.34
"0001) and the time to peak concentration was shortest for this group (P=0."( Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol.
Aronsson, A; Fiala, C; Gemzell-Danielsson, K; Granath, F; Schweer, H; Stephansson, O; Watzer, B, 2007
)
0.34
" To aid the design of effective and safe regimens, we have investigated the pharmacokinetic parameters after the vaginal or sublingual administration of repeated doses of 400 microg of misoprostol."( Pharmacokinetics of repeated doses of misoprostol.
Ho, PC; Lee, SW; Schweer, H; Tang, OS, 2009
)
0.35
" The developed assay method was applied to an oral pharmacokinetic study in humans."( Development and validation of highly sensitive method for determination of misoprostol free acid in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study.
Bhushan, I; Hotha, KK; Jagadeesh, B; Patil, U; Vijaya Bharathi, D, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
"The peak plasma level of MPA after each dose of misoprostol is higher and the bioavailability is also greater after sublingual administration, compared with that after vaginal administration, of repeated doses of misoprostol."( Pharmacokinetics of repeated doses of misoprostol.
Ho, PC; Lee, SW; Schweer, H; Tang, OS, 2009
)
0.35
" The mean bioavailability measured as the area under the curve (AUC) and maximum concentration (C(max)) appeared higher in the control than in the BV group (1458."( Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.
Fiala, C; Gemzell-Danielsson, K; Sandström, A; Schweer, H; Sioutas, A; Watzer, B, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346343Human EP3 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346308Human EP2 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346427Human EP4 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.88)18.7374
1990's3 (17.65)18.2507
2000's5 (29.41)29.6817
2010's6 (35.29)24.3611
2020's2 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.56 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (23.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other12 (70.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]